celares GmbH is devoted to serve its customers with the best solutions for their specific needs. Importantly, our service philosophy is not restricted to known and published approaches, thus our scientists are able to offer out-of-the-box solutions, when appropriate. Beyond that, we have developed novel technologies in the area of molecule multiplexing that we offer to our customers, if suited to their needs. Our molecule multiplexing approach works for both, small and large molecules. Moreover, our team has developed a technology that allows the fast covalent coating of surfaces with many different molecules (see Figure).
PaSmax® is a branched PEG-based crosslinker to connect small-molecules to biologics in unequal ratio. Whereas traditional linear conjugation results in a 1 : 1 ratio between the two connected entities, the use of PaSmax® allows to attach 3 or even 6 small-molecules at once, e.g., toxins or therapeutic drugs, to the biological moiety. Moreover, due to PEG serving as a solubility modulator, even highly hydrophobic small-molecules, such as paclitacel, can be made soluble in aqueous solution. Thus, PaSmax® is the ideal linker to increase the payload of biologics with small-molecule drugs. Antibody drug conjugates (ADCs) for off-cancer indications are particularly suited, since drug-antibody ratios (DARs) of up to 24 are easily achieved.
PEGylation of biomolecules is an effective method to optimize biopharmaceutical drugs by increasing protease stability, decreasing immunogenicity and delaying renal excretion. However, linear PEGylated biologics that require high dosages and concentrated solutions tend to become too viscous for injection. To address this viscosity problem, celares has developed novel mono-dispersed, branched PEGs that substantially reduces the viscosity of PEGylated biologics, compared to linear the PEGylated analogs, while maintaining the positive properties of the chemical modification. This system is called celaSYS.
celaSTAR is a non-dispersed polymer for the tetramerization of molecules, e.g., antigen binding proteins. celaSTAR is co-developed by celares GmbH and Scil Proteins GmbH and is characterized by defined structures and adjustable linker lengths. As a result, the tetrameric conjugates show decelerated renal clearance and extraordinary high multivalent effects.
The fast, reproducible and uniform covalent modification of surfaces with molecules relevant for analytical applications, e.g., antigens, antibodies or oligonucleotides, is a major issue in diagnostics. In addition, fully automated spotting of one or many different compounds in nanoliter scale is a prerequisite for mass production of the assays. A novel surface modifying technology called celaCLICK has been developed by celares in collaboration with Boehringer-Ingelheim that provides a solution for the above mentioned problems.
We offer our technologies in attractive license agreements.